Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) will likely be posting its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.28) per share for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 20, 2026 at 4:00 PM ET.
Brainstorm Cell Therapeutics Trading Down 3.5%
Shares of BCLI stock opened at $0.67 on Tuesday. The company has a market capitalization of $7.39 million, a price-to-earnings ratio of -0.20 and a beta of 0.22. The firm has a 50-day moving average price of $0.80 and a 200 day moving average price of $0.68. Brainstorm Cell Therapeutics has a twelve month low of $0.46 and a twelve month high of $1.92.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
Further Reading
- Five stocks we like better than Brainstorm Cell Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
